Patients with chronic kidney disease (CKD) and heart failure (HF)
SGLT2 inhibitors
SGLT2 inhibitors have pleiotropic mechanisms that reduce CKD progression and improve survival in heart failure patients, highlighting their role as a cornerstone in HF management.
Beyond their glucose-lowering effects, SGLT2is provide significant benefits in patients with chronic kidney disease (CKD) and HF, reducing the progression of CKD and improving overall survival. The pleiotropic actions of SGLT2is highlight their potential as a cornerstone in HF management. Further research is needed to fully elucidate their mechanisms and optimize their use in clinical practice.
Building similarity graph...
Analyzing shared references across papers
Loading...
Piperis et al. (Fri,) studied this question.
synapsesocial.com/papers/6a0662de3f8bf83a443dd95d — DOI: https://doi.org/10.3390/biomedicines12102314
Christos Piperis
General Hospital of Athens G. Genimatas
Anastasios Marathonitis
National and Kapodistrian University of Athens
Artemis Anastasiou
Chest Diseases Hospital
Biomedicines
National and Kapodistrian University of Athens
Sotiria General Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...